Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

NCT01309126 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

217

Enrollment

INDUSTRY

Sponsor class

Stopped Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, the study has been terminated. No patients remain on study.

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: Imprime PGG + cetuximab
DRUG: Cetuximab

Sponsor

HiberCell, Inc.